OBJECTIVE Cases of acute pancreatitis have been reported in association with exenatide,
sitagliptin, and type 2 diabetes without use of these medications. It remains unknown …

Abstract Diabetes mellitus type 2 (DMT2) is a highly prevalent disease both in the United
States and worldwide. Multiple treatment options are currently available, and several new …

Background and Objectives: Sitagliptin is a dipepidyl peptidase inhibitor (DPP-4i) with
gentle antidiabetic effects with a lower risk of hypoglycemia. The association with acute …

Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) play an increasing role in
the management of type 2 diabetes. Such incretin-based therapies offer some advantages …

ABSTRACT… Objectives: To determine the frequency of acute pancreatitis in patients taking
sitagliptin and metformin. A study conducted on 100 type II diabetic patients. Study design: It …

Objective To report the first postmarketing case of necrotizing pancreatitis in a patient on
combination therapy of sitagliptin and exenatide. Methods We describe the patient's clinical …

Incretin-based therapy for type 2 diabetes mellitus with glucagonlike peptide 1 (GLP-1)
receptor agonists (eg, exenatide, liraglutide) and dipeptidyl-dipeptidase 4 (DPP-4) inhibitors …

Objective To report a case of linagliptin-induced acute pancreatitis and remind clinicians
about risks with incretin-based drugs. Patients at risk for pancreatitis should be switched to …

Context To report a case of acute necrotizing pancreatitis in a patient receiving vildagliptin.
Case report A 49-year-old man presented to us with severe abdominal pain and was …

Purpose To evaluate the risk of acute pancreatitis hospitalization with sitagliptin use in
patients with type 2 diabetes mellitus (T2DM). Methods This retrospective cohort analysis …